Method of diagnosing neoplasms

Patent metadata

Field	Value
Publication number	US-2018100200-A1
Application number	US-201715809162-A
Country	US
Kind code	A1
Filing date	Nov 10, 2017
Priority date	Oct 23, 2007
Publication date	Apr 12, 2018
Grant date	—

Abstract

The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.

First claim

1 . A method of screening for the onset or predisposition to the onset of a large intestine neoplasm or monitoring the progress of a neoplasm in an individual, said method comprising measuring the level of expression of one or more genes or transcripts selected from:
(i) the gene, genes or transcripts detected by Affymetrix probeset IDs:
205513_at; and/or
(ii) TCN1 in a biological sample from said individual wherein a higher level of expression of the genes or transcripts of group (i) and/or group (ii) relative to control levels is indicative of a neoplastic large intestine cell or a cell predisposed to the onset of a neoplastic state.

2 . The method according to claim 1 wherein said control level is a non-neoplastic level.

3 . The method according to claim 1 wherein said neoplastic cell is an adenoma or an adenocarcinoma.

4 . The method according to claim 1 wherein said cell is a colorectal cell.

5 . The method according to claim 1 wherein said biological sample is a faecal sample, enema wash, surgical resection, tissue biopsy or blood sample.

6 . The method according to claim 1 wherein said level of expression is mRNA expression or protein expression.

7 . The method according to claim 1 wherein said biological sample is a fecal sample, enema wash, surgical resection, tissue biopsy or blood sample.

8 . The method according to claim 1 wherein said individual is a human.

Assignees

• Clinical Genomics Pty Ltd
• Commw Scient Ind Res Org

Inventors

• Lapointe Lawrence Charles
• Dunne Robert
• Young Graeme P
• Lockett Trevor John
• Wilson William J

Classifications

• G01N2800/06

  Gastro-intestinal diseases · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• G01N33/5753

  of the stomach or small intestine · CPC title

• C12Q2600/158

  Expression markers · CPC title